Pathogenesis of MASLD and MASH – role of insulin resistance and lipotoxicity
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Summary: Background: Insulin resistance and lipotoxicity are extremely interconnected but fundamental in setting the stage for the development of MASLD/MASH. Aim/Methods: A comprehensive literature search was performed and key themes were synthesised to provide insight into the underlying molecular mechanisms of insulin resistance and lipotoxicity in the liver, muscle, pancreas and adipose tissue and how organ cross‐talk is fundamental to driving disease pathogenesis. Results: Classical thinking postulates that excess FFA load exceeds the storage capacity of adipose tissue, which is predicated upon both genetic and environmental factors. This results in insulin resistance and compensatory hyperinsulinaemia by pancreatic beta cells to overcome target organ insulin resistance. As adipocyte dysfunction worsens, not only are excess FFA delivered to other organs, including skeletal muscle, pancreas and liver but a pro‐inflammatory milieu is established with increases in IL‐6, TNF‐α and changes in adipokine levels (increased leptin and decreased adiponectin). With increased intramuscular lipid accumulation, lipotoxic species decrease insulin signalling, reduce glucose uptake by downregulation of GLUT4 and decrease glycogen synthesis. With this additional reduced capacity, hyperglycaemia is further exacerbated and increased FFA are delivered to the liver. The liver has the largest capacity to oxidise fat and to adapt to these stressors and, therefore, has become the last line of defence for excess lipid storage and utilisation, the capacity of which may be impacted by genetic and environmental factors. However, when the liver can no longer keep up with increasing FFA delivery and DNL, lipotoxic species accumulate with ensuing mitochondrial dysfunction, increased ER stress, oxidant stress and inflammasome activation, all of which drive hepatocyte injury and apoptosis. The resulting wound healing response, marked by stellate cell activation, drives collagen accumulation, progressive fibrosis, and, ultimately, end organ failure and death. This vicious cycle and complex interplay between insulin resistance, hyperinsulinaemia, lipotoxicity and multi‐directional cross‐talk among different target organs are critical drivers of MASLD/MASH. Conclusions: Targeting tissue‐specific insulin resistance and hyperinsulinaemia while decreasing FFA load (lipotoxicity) through dietary and lifestyle changes remain the best upstream interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Home visits: a strategy to improve newborn survival - Authors' reply
(2008) · Americanae (AECID Library) · doi:10.1016/s0140 · Cited by 22,524
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
Macrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733
Mechanisms for Insulin Resistance: Common Threads and Missing Links
Samuel, V. T., & Shulman, G. I. (2012) · Cell · doi:10.1016/j.cell.2012.02.017 · Cited by 2,294 · cited 1×
“84 More specifically, DAGs inhibit insulin signalling by increasing protein kinase C ε (PKC ε ), which inhibits IRS1 and 2.”
BackgroundSkeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
DeFronzo, R. A., & Tripathy, D. (2009) · Diabetes Care · doi:10.2337/dc09-s302 · Cited by 2,102 · cited 1×
“57 Continuous exposure to high insulin has been shown to promote both serine/threonine phosphorylation, thereby decreasing IRS1 and GLUT4 translocation to the plasma membrane, both of which promote insulin resistance in skeletal muscle.”
BackgroundA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 1×
“99 However, drugs that improve insulin sensitivity without weight loss, such as Metformin, do not have an impact on MASH or fibrosis.”
BackgroundMechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002 · cited 2×
“22,77 Insulin resistance and hyperinsulinaemia further exacerbate lipid accumulation by diverting glucose away from glycogen synthesis, redirecting it instead to lipogenic pathways.”
BackgroundDulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein
Sun, X. J., Rothenberg, P., Kahn, C. R., Backer, J. M., Araki, E., Wilden, P. A., Cahill, D. A., Goldstein, B. J., & White, M. F. (1991) · Nature · doi:10.1038/352073a0 · Cited by 1,574 · cited 1×
“7,8 Once this cellular cascade is activated, insulin promotes glucose uptake into muscle and adipocytes via GLUT4 transporters, inhibits hepatic glucose release and fat cell lipolysis and promotes lipid accumulation in hepatocytes and adipocytes.”
BackgroundChait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529
Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene
Araki, E., Lipes, M. A., Patti, M.-E., Brüning, J. C., Haag III, B., Johnson, R. S., & Kahn, C. R. (1994) · Nature · doi:10.1038/372186a0 · Cited by 1,252 · cited 1×
“7,8 Once this cellular cascade is activated, insulin promotes glucose uptake into muscle and adipocytes via GLUT4 transporters, inhibits hepatic glucose release and fat cell lipolysis and promotes lipid accumulation in hepatocytes and adipocytes.”
BackgroundHolland, W. L., Brozinick, J. T., Wang, L.-P., Hawkins, E. D., Sargent, K. M., Liu, Y., Narra, K., Hoehn, K. L., Knotts, T. A., Siesky, A., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.01.002 · Cited by 1,232
Lipid-induced insulin resistance: unravelling the mechanism
Samuel, V. T., Petersen, K. F., & Shulman, G. I. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60408-4 · Cited by 1,189
Koliaki, C., Szendroedi, J., Kaul, K., Jelenik, T., Nowotny, P., Jankowiak, F., Herder, C., Carstensen, M., Krausch, M., Knoefel, W. T., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.04.004 · Cited by 1,032
Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity
Fabbrini, E., Magkos, F., Mohammed, B. S., Pietka, T., Abumrad, N. A., Patterson, B. W., Okunade, A., & Klein, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904944106 · Cited by 972
Splanchnic lipolysis in human obesity
Nielsen, S., Guo, Z., Johnson, C. M., Hensrud, D. D., & Jensen, M. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21047 · Cited by 933
A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712191 · Cited by 827 · cited 2×
“What was previously known as non-alcoholic fatty liver disease (NAFLD) was changed to metabolic dysfunction-associated steatotic liver disease (MASLD) and MASH, previously known as non-alcoholic steatohepatitis (NASH), was changed to metabolic dysfunction-associated steatohepatitis.”
BackgroundHarrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802
Self-citationBugianesi, E., Gastaldelli, A., Vanni, E., Gambino, R., Cassader, M., Baldi, S., Ponti, V., Pagano, G., Ferrannini, E., & Rizzetto, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1682-x · Cited by 770
The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome
Petersen, K. F., Dufour, S., Savage, D. B., Bilz, S., Solomon, G., Yonemitsu, S., Cline, G. W., Befroy, D., Zemany, L., Kahn, B. B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705408104 · Cited by 759
Jheng, H.-F., Tsai, P.-J., Guo, S.-M., Kuo, L.-H., Chang, C.-S., Su, I.-J., Chang, C.-R., & Tsai, Y.-S. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.05603-11 · Cited by 650 · cited 1×
“…themes are emerging: (1) lipotoxicity in muscle prompts excessive mitochondrial fission resulting in impaired insulin-stimulated glucose uptake 60 ; (2) increased lipid-derived toxic intermediates from incomplete beta-oxidation such as acylcarnitine 61 and long-chain 62 fatty acyl CoAs, 61…”
BackgroundLiu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5309 · Cited by 623 · cited 3×
“When patients with biopsy-proven MASH were genotyped for the PNPLA3-rs738409 (minor allele: G), TM6SF2-rs58542926 (minor allele: T) and HSD17B13-rs72613567 (minor allele: TA) variants, it was found that the addition of these genetic markers into the prediction of advanced fibrosis (baseline model: age, sex, BMI, diabe…”
BackgroundInfluentialLassailly, G., Caiazzo, R., Ntandja-Wandji, L.-C., Gnemmi, V., Baud, G., Verkindt, H., Ningarhari, M., Louvet, A., Leteurtre, E., Raverdy, V., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.006 · Cited by 622 · cited 1×
“89–91 FFAs are one of the agents able to activate UPR – this is reviewed elsewhere.”
BackgroundDongiovanni, P., Petta, S., Maglio, C., Fracanzani, A. L., Pipitone, R., Mozzi, E., Motta, B. M., Kaminska, D., Rametta, R., Grimaudo, S., et al. (2015) · Hepatology · doi:10.1002/hep.27490 · Cited by 533
Leptin, Obesity, and Leptin Resistance: Where Are We 25 Years Later
Izquierdo, A. G., Crujeiras, A. B., Casanueva, F. F., & Carreira, M. C. (2019) · Nutrients · doi:10.3390/nu11112704 · Cited by 525 · cited 1×
“50 Indeed, higher levels of leptin are associated with obesity.”
BackgroundSamuel, V. T., Liu, Z.-X., Wang, A., Beddow, S. A., Geisler, J. G., Kahn, M., Zhang, X.-M., Monia, B. P., Bhanot, S., & Shulman, G. I. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30400 · Cited by 497
Shepherd, J. A., Ng, B. K., Sommer, M. J., & Heymsfield, S. B. (2017) · Bone · doi:10.1016/j.bone.2017.06.010 · Cited by 460
Hong, S.-H., & Choi, K. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020494 · Cited by 390
A Gut Microbiome Signature for Cirrhosis Due to Nonalcoholic Fatty Liver Disease
Caussy, C., Tripathi, A., Humphrey, G., Bassirian, S., Singh, S., Faulkner, C., Bettencourt, R., Rizo, E., Richards, L., Xu, Z. Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09455-9 · Cited by 338 · cited 1×
“21,22 Moreover, a number of SNPs that are more common in certain ethnic groups have emerged as predictors of disease severity, bringing together both steatosis and fibrosis and are reviewed extensively elsewhere.”
BackgroundBasuRay, S., Smagris, E., Cohen, J. C., & Hobbs, H. H. (2017) · Hepatology · doi:10.1002/hep.29273 · Cited by 302
Nolan, C. J., & Prentki, M. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164119827611 · Cited by 292 · cited 1×
“…the changing dietary patterns, there a number of factors that may predispose one to hyperinsulinaemia including (1) hyperres-ponsiveness of β cells 14 ; (2) fetal programming or epigenetic factors due to intrauterine environment 15 ; (3) endocrine disrupting chemicals 16 ; and (4) reduced hepatic…”
BackgroundMetformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis
LI, Y., LIU, L., WANG, B., WANG, J., & CHEN, D. (2013) · Biomedical Reports · doi:10.3892/br.2012.18 · Cited by 290
De Vincentis, A., Tavaglione, F., Jamialahmadi, O., Picardi, A., Antonelli Incalzi, R., Valenti, L., Romeo, S., & Vespasiani-Gentilucci, U. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.05.056 · Cited by 158
Protein Folding in the Endoplasmic Reticulum and the Unfolded Protein Response
Zhang, K., & Kaufman, R. J. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-29717-0_3 · Cited by 152
Intramuscular triacylglycerol and insulin resistance: guilty as charged or wrongly accused?
Muoio, D. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.11.007 · Cited by 137 · cited 3×
“59 While detailed mechanistic studies are outlined else-where 10 the following themes are emerging: (1) lipotoxicity in muscle prompts excessive mitochondrial fission resulting in impaired insulin-stimulated glucose uptake 60 ; (2) increased lipid-derived toxic intermediates from incomplete beta-oxidation such as acyl…”
BackgroundEarly-Life Origins of Type 2 Diabetes: Fetal Programming of the Beta-Cell Mass
Portha, B., Chavey, A., & Movassat, J. (2011) · Experimental Diabetes Research · doi:10.1155/2011/105076 · Cited by 127 · cited 1×
“…one to hyperinsulinaemia including (1) hyperres-ponsiveness of β cells 14 ; (2) fetal programming or epigenetic factors due to intrauterine environment 15 ; (3) endocrine disrupting chemicals 16 ; and (4) reduced hepatic clearance of insulin 17 which may be increased in African Americans.”
BackgroundMitochondrial involvement in skeletal muscle insulin resistance: A case of imbalanced bioenergetics
Affourtit, C. (2016) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2016.07.008 · Cited by 67
Margolis, R., & Sant, K. E. (2021) · Journal of Xenobiotics · doi:10.3390/jox11030008 · Cited by 59
Cited by
Youhanna, S., Taebnia, N., Liang, Y., Cheng, N., Wang, Y., Michel, M., & Lauschke, V. M. (2025) · Advanced Biology · doi:10.1002/adbi.202500337 · Cited by 9
Metadata
- Authors
- Bansal, S. K., & Bansal, M. B.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2024-03-07
- Volume
- 59
- Issue
- S1
- Pages
- S10-S22
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W4392561936
- Cited by
- 178
- References
- 39
- FWCI
- 46.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.